Year: 2021

2020 and 2021 – Sales (in $’million)2020 and 2021 – Sales (in $’million)MONTREAL, Nov. 15, 2021 (GLOBE NEWSWIRE) — Dynacor Gold Mines Inc. (TSX: DNG) (Dynacor or the Corporation) released its unaudited consolidated financial statements and the management’s discussion and analysis (MD&A) for the third quarter ended September 30, 2021. These documents have been filed electronically with SEDAR at www.sedar.com and will be available on the Corporation’s website www.dynacor.com. (All figures in this press release are in Ms of US$ unless stated otherwise. All amounts per share are in US$. All variance % are calculated from rounded figures. Some additions might be incorrect due to rounding). Q3-2021 OVERVIEW AND HIGHLIGHTS OVERVIEW Dynacor completed the three-month period ended...

Company delivers strong sales, earnings growth; announces productivity savings initiative SPRINGDALE, Ark., Nov. 15, 2021 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, today reported the following results:(in millions, except per share data) Fourth Quarter   Twelve Months Ended  2021   2020   2021   2020Sales $ 12,811     $ 11,460     $ 47,049     $ 43,185  Operating Income 1,909     962     4,396     3,008                 Net Income 1,358     657     3,060     2,071  Less: Net Income Attributable to Noncontrolling Interests 3     3     13     10  Net Income Attributable to Tyson $ 1,355     $ 654     $ 3,047     $ 2,061  Net...

ROSELAND, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the third quarter ended September 30, 2021. Arjan Haverhals, President and Chief Executive Officer of Milestone Scientific, commented, “We are pleased to report continued revenue growth, achieving a 69% increase in revenue to $2.1 million for the three months ended September 30, 2021. This growth is a reflection of the solid performance of our dental division, as dental offices have been re-opening around the world. We are also starting to see the results of our sales and marketing initiatives within the Medical segment, as illustrated by our recent selection to supply...

Announced Successful Phase 1b trial for YTX-7739 in Parkinson’s disease patients; YTX-7739 was well tolerated and demonstrated target engagement and favorable PK/PD and safety profiles Company anticipates initiating Phase 2 clinical trial of YTX-7739 in patients with Parkinson’s disease in 2022 Appointed Michael D. Wyzga as SVP, Chief Financial Officer BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) — Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2021 and provided an overview of the Company’s recent corporate developments and upcoming milestones. “With the recent announcement of our positive Phase 1b clinical trial...

Financial HighlightsContinued Momentum Across Traditional and Emerging Streaming Platforms Drove Double-Digit Digital Revenue Growth for the Quarter and Full Year Recovery in COVID-Impacted Areas Led by Strong Growth in Artist Services and Physical Revenue Delivered Margin Improvement and Double-Digit Growth in Adjusted OIBDA and Adjusted EBITDA Robust Free Cash Flow Conversion and Growth Underpinned by Strong Operating Leverage and Financially Disciplined InvestmentsFor the three months ended September 30, 2021Total revenue grew 22% or 21% in constant currency Digital revenue grew 19% or 18% in constant currency Net income was $30 million versus $1 million in the prior-year quarter OIBDA increased 15% to $179 million versus $155 million in the prior-year quarter Adjusted OIBDA increased 25% to $218 million versus $174 million...

SCOTTSDALE, Ariz., Nov. 15, 2021 (GLOBE NEWSWIRE) — AgJunction Inc. (TSX: AJX) (“AgJunction” or the “Company”) is reporting financial results for the third quarter ended September 30, 2021. All currency amounts are expressed in U.S. dollars. Third Quarter 2021 Financial Summary vs. Third Quarter 2020Revenue was $3.7 million compared to $3.8 million Gross margin increased to 50.9% compared to 49.7% Operating expenses increased to $4.2 million compared to $3.1 million $1.5 million one-time gain on Paycheck Protection Plan (“PPP”) loan forgiveness Net loss was $(0.9) million or $(0.01) per share, compared to a net loss of $(1.3) million or $(0.01) per share EBITDA was $0.1 million compared to $(0.6) million    Management Commentary “Our team continued to work hard during the quarter maintaining strong relationships...

Third Quarter 2021 Revenues of $140 million and Marketplace GOV of $713 million CHICAGO, Nov. 15, 2021 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats”, “we” or the “Company”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today provided financial results for the quarter ended September 30, 2021. “The record-setting results we saw in the third quarter are a great way to mark our first reported results as a public company. Live events have come back stronger than expected as fans returned to support their favorite sports teams and artists. We are committed to delivering fans an exceptional experience so they can get out and do what they love,” said Stan Chia, Vivid Seats CEO. “We...

ULAANBAATAR, Mongolia, Nov. 15, 2021 (GLOBE NEWSWIRE) — Steppe Gold Ltd (TSX: STGO) (OTCQX:STPGF) (FSE:2J9) (“Steppe Gold” or the “Company”) announces that it has filed on SEDAR its financial results for the quarter ended September 30, 2021. The full version of the Condensed Interim Consolidated Financial Statements and Management’s Discussion & Analysis can be viewed on the Company’s website at www.steppegold.com or under the Company’s profile on SEDAR at www.sedar.com.  Amounts are expressed in United States dollars unless otherwise noted. Steppe Gold Limited Steppe Gold is Mongolia’s premier precious metals company. For Further information, please contact: Bataa Tumur-Ochir, CEO and President Jeremy South, Senior Vice President and CFO Shangri-La office, Suite 1201, Olympic street19A, Sukhbaatar District...

YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the third quarter ended September 30, 2021. “We continue to make important progress across our extensive portfolio, as we generate and publish new and compelling data highlighting the potential meaningful improvements for patients that we have observed in a variety of difficult to treat infections. Our primary focus remains on the enrollment of patients in the Phase 3 DISRUPT superiority study of our Breakthrough Therapy, new modality drug,...

Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate Additional Phase 2b Data Prior to Initiating Pivotal Phase 3 Program Determining Optimal Enrollment for Phase 2 Clinical Study of Omilancor in Crohn’s Disease and Phase 1b Study of NX-13 in UC Initiated Dosing for LABP-104 in Healthy Volunteers in October 2021 with Results Expected in 1H 2022 Corporate Update Conference Call Scheduled for 8:00 am ET Today BLACKSBURG, Va., Nov. 15, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases, today announced financial results for the third...